NexImmune, Inc.

NexImmune, Inc.: Clinical-stage IO company developing unique approach to antigen-specific T cell therapy. Synthetic nanoparticles decorated w a combo of multiple tumor relevant antigens and co-stimulatory signals engaging directly w targeted T cells to orchestrate specific immune responses to cancer. Product applications as both SQ injectable and adoptively transferred cellular therapy. Two Ph 1's ongoing.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Immuno-Oncology, Oncology
Industry
Biotechnology, Pharmaceuticals
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy
Website:
Profiles:
Address:
9119 Gaither Road
Gaithersburg, MD 20877
United States

Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13

  • Scott Carmer, President/CEO

Top 10 Holders of NexImmune, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
ArrowMark Colorado Holdings LLC 11.21 2,415,475 57.71 Stakes 2/12/21
Invus Public Equities Advisors LLC 5.57 1,200,000 28.67 Stakes 2/17/21
Allen Holding, Inc. 2.95 635,934 15.19 Stakes 2/12/21
Fidelity Management & Research Co. LLC 2.44 525,000 12.54 Funds 2/28/21
The Vanguard Group, Inc. 0.52 111,567 2.67 Funds 2/28/21
TimesSquare Capital Management LLC 0.14 29,300 0.70 Funds 2/26/21
Geode Capital Management LLC 0.04 8,438 0.20 Funds 2/28/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.